GoldenGolden
Advanced Search
Gamida Cell

Gamida Cell

Gamida Cell is a biotechnology company developing cell therapies for treating cancer and hematologic diseases.

Gamida Cell is a company that is interested in providing cell-based therapeutics to assist patients that have life threatening blood diseases. The company was founded in 1998 by Tony Peled, in Jerusalem, Yerushalayim, Israel.

Gamida Cell's mission is to develop potentially curative cell therapies for the purpose of assisting patients with cancer. The company has developed celullar therapies such as Omidubicel which is meant to help treat high-risk hematologic malignancies, severe aplastic anemia, non-hodgkin lymphoma, and multiple myeloma.

The company has developed a platform that has the potential to provide treatment options for patients with blood, and allows for the expansion of the uses of stem cells or natural killer cells, while maintaining their original phenotype and potency.

Gamida Cell's platform is based on expanded populations of cord blood stem cells and creating regenerative and therapeutic stem cells. They are known to operate in the medical device and therapeutics fields.

Timeline

1998
Gamida Cell was founded.

Patents

People

Name
Role
LinkedIn

Further reading

Title
Author
Link
Type
Date

Gamida Cell Announces Immune Reconstitution Data from Completed Phase 1/2 Clinical Study of NiCord® Presented at 2019 TCT Annual Meeting

Business Wire

Web

Gamida Cell teams up with Be The Match BioTherapies to help develop its bone marrow transplant alternative

Conor hale

Web

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
BioSpace
June 7, 2021
BioSpace
Gamida Cell Ltd., an advanced cell therapy company committed to cures for blood cancers and serious blood diseases, announced the appointment of Vladimir Melnikov as senior vice president, global operations and manufacturing.

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.